Overall Outcomes and Factors Predicting the Success of Endoscopic Dextranomer/Hyaluronic Acid Copolymer Injection for Vesicoureteral Reflux

Purpose: We aimed to evaluate the overall outcomes of endoscopic dextranomer/hyaluronic acid copolymer (Deflux) injection for vesicoureteral reflux (VUR) and analyze the factors predicting success. Materials and Methods: A total 99 patients (58 males, 41 females) and 154 refluxing ureter units were treated with a endoscopic Deflux injection for VUR. At 3 months, radioisotope-voiding cystograms were performed to evaluate treatment responsiveness; success was defined as a resolving of VUR to less than grade I. We evaluated various perioperative factors such as gender, operation age, preoperative antibiotics duration, urinary tract infection, relative renal function and cortical defect, preoperative VUR grade, maximal flow rate in uroflowmetry, laterality of reflux, voiding dysfunction, constipation, orifice shape and trabeculation, injection technique, injection volume, number of punctures, and learning curve. Results: The overall success rate was 62.3% (96/154) in refluxing ureter units (50.5% in patients). According to grade of VUR, the success rate was 87.5% (8/9), 82.2% (37/45), 67.8% (38/56), 33.3% (13/39), and 16.7% (1/6) in grade I, II, III, IV, and V, respectively (p=0.001). In multivariate analysis, preoperative VUR grade and mound morphology were identified as predictive factors (p<0.05). No significant surgery-related complications developed. Conclusions: Endoscopic Deflux injection for VUR was effective for grade I-III VUR, although the cure rate was low for grade IV-V. The factors predicting success were preoperative VUR grade and mound morphology. (Korean J Urol 2009;50:51-56)

[1]  A. Wein,et al.  Campbell-Walsh Urology , 2011 .

[2]  D. Bägli,et al.  Learning from the learning curve: factors associated with successful endoscopic correction of vesicoureteral reflux using dextranomer/hyaluronic acid copolymer. , 2008, The Journal of urology.

[3]  W. Snodgrass,et al.  Urinary tract infection following successful dextranomer/hyaluronic acid injection for vesicoureteral reflux. , 2008, The Journal of urology.

[4]  P. Puri,et al.  The role of endoscopic treatment in the management of grade v primary vesicoureteral reflux. , 2007, European urology.

[5]  P. Puri,et al.  Endoscopic treatment of moderate and high grade vesicoureteral reflux in infants using dextranomer/hyaluronic acid. , 2007, The Journal of urology.

[6]  Y. Park,et al.  Dextranomer/Hyaluronic Acid Copolymer (Deflux®) Injection for Vesicoureteral Reflux in Children: the Efficacy and Safety , 2007 .

[7]  W. Snodgrass,et al.  Multivariate analysis of factors predicting success with dextranomer/hyaluronic acid injection for vesicoureteral reflux. , 2007, The Journal of urology.

[8]  M. Çakan,et al.  Are there predictive factors for the outcome of endoscopic treatment of grade III–V vesicoureteral reflux with dextranomer/hyaluronic acid in children? , 2007, Pediatric Surgery International.

[9]  I. H. Chang,et al.  Predictive Factor to Regain Erectile Function after Bilateral Nerve Sparing Radical Retropubic Prostatectomy in Korean Men , 2007 .

[10]  D. Roth,et al.  Treatment of Vesicoureteral Reflux Using Endoscopic Injection of Nonanimal Stabilized Hyaluronic Acid/Dextranomer Gel: Initial Experience in Pediatric Patients by a Single Surgeon , 2006, Pediatrics.

[11]  J. Pope,et al.  Endoscopic therapy for vesicoureteral reflux: a meta-analysis. I. Reflux resolution and urinary tract infection. , 2006, The Journal of urology.

[12]  M. Lavelle,et al.  Subureteral injection of Deflux for correction of reflux: analysis of factors predicting success. , 2005, Urology.

[13]  P. O'dwyer,et al.  Endoscopic , 2021 .

[14]  P. Caione,et al.  The role of endoscopic treatment of vesicoureteral reflux: a 17-year experience. , 2004, The Journal of urology.

[15]  A. Kirsch,et al.  Endoscopic treatment with dextranomer/hyaluronic acid for complex cases of vesicoureteral reflux. , 2004, The Journal of urology.

[16]  P. Puri,et al.  Treatment of vesicoureteral reflux by endoscopic injection of dextranomer/hyaluronic Acid copolymer: preliminary results. , 2003, The Journal of urology.

[17]  D. Canning Medical versus surgical treatment in children with severe bilateral vesicoureteric reflux and bilateral nephropathy: a randomised trial. , 2003, The Journal of urology.

[18]  A. Kirsch,et al.  Minimally invasive treatment of vesicoureteral reflux with endoscopic injection of dextranomer/hyaluronic acid copolymer: the Children's Hospitals of Atlanta experience. , 2003, The Journal of urology.

[19]  P. Puri,et al.  Treatment of vesicoureteric reflux by endoscopic injection of Teflon. , 1984, The Journal of urology.

[20]  G. McLorie,et al.  Efficacy of endoscopic subureteral polydimethylsiloxane injection for treatment of vesicoureteral reflux in children: a North American clinical report. , 2001, The Journal of urology.

[21]  G. Läckgren,et al.  Long-term followup of children treated with dextranomer/hyaluronic acid copolymer for vesicoureteral reflux. , 2001, The Journal of urology.

[22]  A. Sundin,et al.  Lack of distant migration after injection of a 125iodine labeled dextranomer based implant into the rabbit bladder. , 1997, The Journal of urology.

[23]  G. Läckgren,et al.  A new bioimplant for the endoscopic treatment of vesicoureteral reflux: experimental and short-term clinical results. , 1995, The Journal of urology.

[24]  A. Bechara,et al.  [Treatment of vesicoureteral reflux by endoscopic injection of teflon]. , 1985, Archivos espanoles de urologia.